Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
117.28
+1.53 (1.32%)
At close: Jan 22, 2026, 4:00 PM EST
117.28
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:21 PM EST
Guardant Health Revenue
Guardant Health had revenue of $265.20M in the quarter ending September 30, 2025, with 38.50% growth. This brings the company's revenue in the last twelve months to $902.57M, up 30.38% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$902.57M
Revenue Growth
+30.38%
P/S Ratio
15.92
Revenue / Employee
$446,595
Employees
2,021
Market Cap
15.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.77B |
| Quest Diagnostics | 10.85B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.29B |
| Charles River Laboratories International | 4.02B |
| Mettler-Toledo International | 3.94B |
| Waters | 3.11B |
| Exact Sciences | 3.08B |
GH News
- 3 hours ago - FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
- 8 hours ago - Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
- 11 hours ago - Alger Mid Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 3 days ago - Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Business Wire
- 4 days ago - Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth - Seeking Alpha
- 9 days ago - Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results - Business Wire
- 14 days ago - Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families - Business Wire